{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:16:01Z","timestamp":1789676161085,"version":"4.0.1"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1097\/wnf.0b013e31824150a5","type":"journal-article","created":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T07:33:06Z","timestamp":1325835186000},"page":"40-44","source":"Crossref","is-referenced-by-count":24,"title":["Drug Interaction and Pharmacokinetic Modeling of Oxcarbazepine in Korean Patients With Epilepsy"],"prefix":"10.1097","volume":"35","author":[{"given":"Kyoung-Jin","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Ryul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Yeon","family":"Joo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Won","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Bong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Wook","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suk-Ran","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wooseong","family":"Huh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Youn","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210203","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2165\/00003088-200342120-00002","article-title":"Clinical pharmacokinetics of oxcarbazepine.","volume":"42","author":"May","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"R2-8-20210203","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1592\/phco.21.11.904.34513","article-title":"Oxcarbazepine in the treatment of epilepsy.","volume":"21","author":"Glauser","year":"2001","journal-title":"Pharmacotherapy"},{"key":"R3-8-20210203","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1053\/seiz.2000.0391","article-title":"Oxcarbazepine: a review.","volume":"9","author":"Shorvon","year":"2000","journal-title":"Seizure"},{"key":"R4-8-20210203","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2165\/0003088-200847120-00002","article-title":"Does oxcarbazepine warrant therapeutic drug monitoring A critical review.","volume":"47","author":"Bring","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"R5-8-20210203","first-page":"200","article-title":". The pharmacokinetic interaction and therapeutic plasma concentration of oxcarbazepine.","volume":"3","author":"Kang","year":"1999","journal-title":"J Korean Epilepsy Soc"},{"issue":"suppl 3","key":"R6-8-20210203","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1111\/j.1528-1157.1994.tb05938.x","article-title":"Clinical pharmacology and pharmacokinetics of oxcarbazepine.","volume":"35","author":"Lloyd","year":"1994","journal-title":"Epilepsia"},{"key":"R7-8-20210203","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/01.ftd.0000155342.93489.fd","article-title":". 10-Hydroxycarbazepine serum concentration-to-oxcarbazepine dose ratio: influence of age and concomitant antiepileptic drugs.","volume":"27","author":"Armijo","year":"2005","journal-title":"Ther Drug Monit"},{"key":"R8-8-20210203","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S0188-4409(00)00056-4","article-title":". Plasma level monitoring of oxcarbazepine in epileptic patients.","volume":"31","author":"Gonzalez-Esquivel","year":"2000","journal-title":"Arch Med Res"},{"key":"R9-8-20210203","first-page":"914","article-title":". Pharmacokinetic variability of oxcarbazepine in epileptic patients.","volume":"60","author":"Viola","year":"2000","journal-title":"Medicina (B Aires)"},{"key":"R10-8-20210203","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF00194967","article-title":". The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites.","volume":"47","author":"Rouan","year":"1994","journal-title":"Eur J Clin Pharmacol"},{"issue":"suppl 3","key":"R11-8-20210203","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1111\/j.1528-1157.1994.tb05939.x","article-title":"Oxcarbazepine: pharmacokinetic interactions and their clinical relevance.","volume":"35","author":"Baruzzi","year":"1994","journal-title":"Epilepsia"},{"key":"R12-8-20210203","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0009-9236(03)00124-3","article-title":". Pharmacokinetic drug interactions in children taking oxcarbazepine.","volume":"74","author":"Sallas","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"R14-8-20210203","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/00003088-200645110-00002","article-title":"Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed Clin P","volume":"45","author":"Johannessen","year":"2006","journal-title":"harmacokinet"},{"key":"R15-8-20210203","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":". Antiepileptic drugsbest practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies.","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"R16-8-20210203","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1034\/j.1600-0404.2001.00870.x","article-title":". Recommendations on the clinical use of oxcarbazepine in the treatment of epilepsy: a consensus view.","volume":"104","author":"Schmidt","year":"2001","journal-title":"Acta Neurol Scand"},{"key":"R17-8-20210203","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/WNF.0b013e3181f80bd4","article-title":". Risk factors of oxcarbazepine-induced hyponatremia in patients with epilepsy.","volume":"33","author":"Lin","year":"2010","journal-title":"Clin Neuropharmacol"},{"key":"R18-8-20210203","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1111\/j.1528-1167.2007.01109.x","article-title":"Rash from antiepileptic drugs: influence by gender, age, and learning disability.","volume":"48","author":"Alvestad","year":"2007","journal-title":"Epilepsia"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002826-201201000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:29:57Z","timestamp":1786048197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002826-201201000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e31824150a5","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}